Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charalampos Moschos

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Neoplasia (New York, N.Y.)|February 27, 2009
The angiopoietin/Tie2 axis mediates malignant pleural effusion formationCharalampos Moschos, Ioannis Psallidas, Androniki Kollintza, et al.
American Journal of Respiratory and Critical Care Medicine|April 5, 2008
Zoledronic acid is effective against experimental malignant pleural effusionGeorgios T Stathopoulos, Charalampos Moschos, Heleni Loutrari, et al.
Neoplasia (New York, N.Y.)|January 14, 2012
Neutralization of tumor necrosis factor bioactivity ameliorates urethane-induced pulmonary oncogenesis in miceSophia P Karabela, Chrysoula A Kairi, Sophia Magkouta, et al.
BMC Pulmonary Medicine|June 2, 2011
Static and dynamic mechanics of the murine lung after intratracheal bleomycinEffrosyni D Manali, Charalampos Moschos, Christina Triantafillidou, et al.
Molecular Cancer|March 12, 2010
Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical studyIoannis Psallidas, Sophia P Karabela, Charalampos Moschos, et al.
Journal of the National Cancer Institute|October 9, 2008
A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusionGeorgios T Stathopoulos, Ioannis Psallidas, Ardiana Moustaki, et al.
Cancer Research|October 19, 2007
Tumor necrosis factor-alpha promotes malignant pleural effusionGeorgios T Stathopoulos, Androniki Kollintza, Charalampos Moschos, et al.
Carcinogenesis|November 20, 2019
Osteopontin drives KRAS-mutant lung adenocarcinomaIoanna Giopanou, Nikolaos I Kanellakis, Anastasios D Giannou, et al.
BMJ Open|June 20, 2020
Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort studySimone Hj van den Elsen, Marieke Gg Sturkenboom, Onno Akkerman, et al.
The European Respiratory Journal|March 12, 2016
Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TBSimon Tiberi, Marie-Christine Payen, Giovanni Sotgiu, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Neoplasia (New York, N.Y.)|February 27, 2009
The angiopoietin/Tie2 axis mediates malignant pleural effusion formationCharalampos Moschos, Ioannis Psallidas, Androniki Kollintza, et al.
American Journal of Respiratory and Critical Care Medicine|April 5, 2008
Zoledronic acid is effective against experimental malignant pleural effusionGeorgios T Stathopoulos, Charalampos Moschos, Heleni Loutrari, et al.
Neoplasia (New York, N.Y.)|January 14, 2012
Neutralization of tumor necrosis factor bioactivity ameliorates urethane-induced pulmonary oncogenesis in miceSophia P Karabela, Chrysoula A Kairi, Sophia Magkouta, et al.
BMC Pulmonary Medicine|June 2, 2011
Static and dynamic mechanics of the murine lung after intratracheal bleomycinEffrosyni D Manali, Charalampos Moschos, Christina Triantafillidou, et al.
Molecular Cancer|March 12, 2010
Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical studyIoannis Psallidas, Sophia P Karabela, Charalampos Moschos, et al.
Journal of the National Cancer Institute|October 9, 2008
A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusionGeorgios T Stathopoulos, Ioannis Psallidas, Ardiana Moustaki, et al.
Cancer Research|October 19, 2007
Tumor necrosis factor-alpha promotes malignant pleural effusionGeorgios T Stathopoulos, Androniki Kollintza, Charalampos Moschos, et al.
Carcinogenesis|November 20, 2019
Osteopontin drives KRAS-mutant lung adenocarcinomaIoanna Giopanou, Nikolaos I Kanellakis, Anastasios D Giannou, et al.
BMJ Open|June 20, 2020
Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort studySimone Hj van den Elsen, Marieke Gg Sturkenboom, Onno Akkerman, et al.
The European Respiratory Journal|March 12, 2016
Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TBSimon Tiberi, Marie-Christine Payen, Giovanni Sotgiu, et al.
Pageof 3